By Sheeba M. | April 13, 2026
Verano Holdings Emerges as a Standout Performer in Crowded MSO Space
Verano Holdings ($VRNO) is flying under the radar compared to larger multi-state operators, but the company’s operational metrics tell a compelling story. With EBITDA margins consistently above 25% — compared to the industry average of 15-20% — Verano is proving that disciplined execution in cannabis operations can generate real profits, not just revenue growth.
Why EBITDA Margins Matter More Than Revenue
In the early days of legal cannabis, scale was everything — companies raced to open as many dispensaries and cultivation facilities as possible, burning through capital to capture market share. But as the industry matures and interest rates remain elevated, profitability has become the metric that separates the winners from the also-rans.
Verano’s focus on operational efficiency shows up in its cultivation strategy. Rather than building massive greenhouse facilities in every state, the company has optimized a smaller footprint of high-yield facilities that serve multiple dispensary locations. This approach reduces capital expenditure requirements while maintaining product quality and supply consistency.
The company’s Arizona operations are particularly noteworthy. In a state where over 100 dispensaries compete for market share, Verano’s locations consistently rank in the top quartile for per-store revenue — a testament to site selection and local brand marketing.
Organigram Deal Signals Strategic Ambitions
Verano’s partnership with Organigram Holdings ($OGI) through the Catalyst cannabis brand represents a strategic expansion of its product portfolio beyond traditional flower and pre-rolls. The collaboration brings high-margin derivative products — including vape cartridges and edibles — into Verano’s dispensary network at competitive wholesale prices.
This type of cross-MSO product partnership is becoming more common as companies seek to diversify revenue without the capital cost of building out extraction and manufacturing capabilities in-house. For Organigram, it provides a ready-made retail channel for its branded products. For Verano, it adds product variety without significant capex.
Valuation Gap Presents Opportunity
Despite superior operational metrics, $VRNO trades at a discount to peers on an EV/EBITDA basis. The market appears to be applying a blanket discount to cannabis stocks due to regulatory uncertainty, failing to differentiate between well-run operators and those burning cash on unprofitable expansion.
If cannabis reform progresses — whether through federal rescheduling or banking reform — this valuation gap could close quickly. Analysts covering the sector note that investors seeking exposure to profitable cannabis companies with sustainable business models should watch Verano closely as a potential re-rating candidate.
For now, the company’s focus on cash generation over growth-at-all-costs makes it one of the more defensive plays in the MSO space — exactly the kind of company that thrives when capital is expensive and patience is required.
Sources
- Nasdaq — Cannabis reclassification and MSO stock analysis
- The Motley Fool — Cannabis stock coverage and investment analysis
Track cannabis stocks with the Weedstock Real-Time Tracker